Evidence map›Paper›PMID 41884241›Full record

ArticleWorld journal of nephrology2026

Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial.

Rodrigo Daza Arnedo, Vicente Sánchez Polo, Jenniffer Benavides Garcia, Juan Felipe Gutiérrez, Enrique Ramos Clason, Daniel Domínguez, Giovany Mera Rebutti, Carlos Madrid Mancia, Rene Tabora López, Manuel Rocha Meza and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Rodrigo Daza ArnedoLatin American Society of Nephrology and Hypertension, Panama City 0810, Panama.
Vicente Sánchez PoloLatin American Society of Nephrology and Hypertension, Panama City 0810, Panama.
Jenniffer Benavides GarciaLatin American Society of Nephrology and Hypertension, Panama City 0810, Panama.
Juan Felipe GutiérrezColombian Association of Nephrology and Arterial Hypertension, Bogota 111211, Colombia.
Enrique Ramos ClasonFaculty of Nursing, University of Cartagena, Health Services Administration Program, Bolivar 130010, Colombia.
Daniel DomínguezLatin American Society of Nephrology and Hypertension, Panama City 0810, Panama.
Giovany Mera RebuttiDepartment of Nephrology, Dr. Abel Gilbert Pontón Hospital of Guayaquil, Ministry of Public Health, Guayaquil 090104, Guayas, Ecuador.
Carlos Madrid ManciaDepartment of Nephrology, Honduran Institute of Social Security, Transplant Committee of the Del Valle Hospital, San Pedro Sula 21101, Cortés, Honduras.
Rene Tabora LópezDepartment of Nephrology, Del Valle Hospital, San Pedro Sula 21101, Cortés, Honduras.
Manuel Rocha MezaLatin American Society of Nephrology and Hypertension, Panama City 0810, Panama.
Dany Tabora LópezDepartment of Nephrology, Del Valle Hospital, San Pedro Sula 21101, Cortés, Honduras.
James J Muñoz ZambranoDepartment of Nephrology, Rafael Rodríguez Zambrano Hospital, Manta 130802, Manabí, Ecuador.
Eduardo Lorca HerreraLatin American Society of Nephrology and Hypertension, Panama City 0810, Panama.
Eliana Dina-BatlleLatin American Society of Nephrology and Hypertension, Panama City 0810, Panama.
Michael Cieza TerronesLatin American Society of Nephrology and Hypertension, Panama City 0810, Panama.
Thyago Proença de MoraesLatin American Society of Nephrology and Hypertension, Panama City 0810, Panama.
Tomas Rodriguez YánezFaculty of Medicine, Department of Internal Medicine, University of Cartagena, Cartagena 130015, Bolívar, Colombia.
Washington OsorioDepartment of Nephrology, Armed Forces Specialty Hospital Number 1, Quito 170150, Pichincha, Ecuador.
Alyi Arellano CabezaDepartment of Internal Medicine, Hospital Universitario del Valle "Evaristo Garcia", University of Valle, Cali 760043, Valle del Cauca, Colombia.
Jorge Rico-FontalvoLatin American Society of Nephrology and Hypertension, Panama City 0810, Panama.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) face high renal and cardiovascular risks. Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, has demonstrated efficacy in reducing these risks in clinical trials. However, its real-world safety and effectiveness remain underexplored in local settings.

aimTo evaluate the real-world safety and effectiveness of finerenone in patients with T2DM and CKD across seven Latin American countries.

methodsWe conducted an observational, multicenter, retrospective cohort study based on real-world data in 347 patients with T2DM and CKD [urinary albumin-creatinine ratio (UACR) > 30 mg/g]. Patients received finerenone (10 mg or 20 mg daily), and clinical and laboratory parameters were evaluated at baseline and after six months of treatment.

resultsAt baseline, median values (interquartile range) were: Glycated hemoglobin A1c 7.6% (6.8%-8.1%); estimated glomerular filtration rate 39.0 mL/minute/1.73 m

conclusionIn our cohort of patients with CKD associated with T2DM, finerenone proved to be an effective short-term therapy for reducing albuminuria, demonstrating very good tolerance and a low risk of hyperkalemia.

Indexed as

AlbuminuriaChronic kidney diseaseDiabetic nephropathyFinerenoneHyperkalemiaType 2 diabetes

Identifiers

PMID41884241
PMCPMC13010476

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.